RIVIVE Drug Patent Profile

✉ Email this page to a colleague

When do Rivive patents expire, and what generic alternatives are available?

Rivive is a drug marketed by Harm Reduction Therp and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-one patent family members in thirty-six countries.

The generic ingredient in RIVIVE is naloxone hydrochloride. There are twelve drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rivive

A generic version of RIVIVE was approved as naloxone hydrochloride by HOSPIRA on September 24^th, 1986.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for RIVIVE?
What are the global sales for RIVIVE?
What is Average Wholesale Price for RIVIVE?

Summary for RIVIVE

International Patents:	51
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in RIVIVE?	RIVIVE excipients list
DailyMed Link:	RIVIVE at DailyMed

Drug patent expirations by year for RIVIVE

Pharmacology for RIVIVE

Drug Class	Opioid Antagonist
Mechanism of Action	Opioid Antagonists

US Patents and Regulatory Information for RIVIVE

RIVIVE is protected by two US patents.

Patents protecting RIVIVE

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF INTRANASAL NALOXONE FOR THE TREATMENT OF OPIOID OVERDOSE

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harm Reduction Therp	RIVIVE	naloxone hydrochloride	SPRAY, METERED;NASAL	217722-001	Jul 28, 2023		OTC	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Harm Reduction Therp	RIVIVE	naloxone hydrochloride	SPRAY, METERED;NASAL	217722-001	Jul 28, 2023		OTC	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for RIVIVE

See the table below for patents covering RIVIVE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
South Korea	101873174		⤷ Sign Up
Ukraine	110974	ІНТРАНАЗАЛЬНІ ФАРМАЦЕВТИЧНІ ДОЗОВАНІ ФОРМИ, ЩО МІСТЯТЬ НАЛОКСОН (INTRANASAL PHARMACEUTICAL DOSAGE FORM COMPRISING NALOXONE)	⤷ Sign Up
Cyprus	1120399		⤷ Sign Up
Malaysia	194947	INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE	⤷ Sign Up
Colombia	6821959	Formas de dosificación farmacéutica intranasales que comprenden naloxona	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for RIVIVE

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg	⤷ Sign Up	PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

AI Research Assistant

Questions you can ask:

Summary for RIVIVE

Pharmacology for RIVIVE

Patents protecting RIVIVE

Make Better Decisions: Try a trial or see plans & pricing